论文部分内容阅读
目的探讨噻唑烷二酮类药物对2型糖尿病患者骨骼的影响。方法 59例2型糖尿病患者出院方案有吡格列酮(噻唑烷二酮类药物)作为研究组,另选取同期36例2型糖尿病患者出院口服药物降糖方案不含吡格列酮(噻唑烷二酮类药物)作为对照组,分析两组骨折、骨痛发生情况。结果研究组发生严重摔伤后骨折患者2例(均为女性),发生率为3.39%;既往无骨痛现出现骨痛患者12例(其中女7例,男5例),发生率为20.34%;无明显骨骼系统症状不适患者45例(76.27%)。对照组无骨折发生情况,仅有1例骨痛患者,发生率为2.78%。研究组骨痛发生率高于对照组,差异具有统计学意义(P<0.05)。结论对绝经后女性、老年人等存在骨折高危风险的糖尿病患者,在使用噻唑烷二酮类药物时应全面评估其骨代谢情况,关注骨密度,预防骨折和骨质疏松的发生。
Objective To investigate the effect of thiazolidinedione on bone in type 2 diabetic patients. Methods Fifty-nine patients with type 2 diabetes were given pioglitazone (thiazolidinedione) as study group. Another 36 patients with type 2 diabetes who underwent oral hypoglycemic discharge without pioglitazone (thiazolidinedione) Control group, analysis of two groups of fractures, bone pain occurred. Results In the study group, there were 2 patients (all female) with fracture, and the incidence rate was 3.39%. There were 12 patients (7 males and 5 females) with bone pain in the past without bone pain, the incidence was 20.34 %; 45 patients (76.27%) had no obvious discomfort of skeletal system symptoms. There was no fracture in the control group, only 1 case of bone pain, the incidence was 2.78%. The incidence of bone pain in the study group was higher than that in the control group, the difference was statistically significant (P <0.05). Conclusion For postmenopausal women, the elderly and other patients at high risk of fracture diabetes, thiazolidinedione should be thoroughly evaluated for bone metabolism, bone mineral density, prevention of fractures and osteoporosis.